CHICAGO — Patients who are new users of glucagon-like peptide-1 (GLP-1) receptor agonists have a low absolute risk of thyroid cancer, according to a new study presented at the American Thyroid Association (ATA) Annual Meeting. The study, presented by Juan Brito Campana, MBBS, of the Mayo Clinic in Rochester…
